Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
65.42
+0.15 (+0.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Courts Find Gilead "Morally Blameworthy" for Withholding HIV Medication
January 23, 2024
January 23, 2024 -- California's Court of Appeals denies Gilead Sciences' request for immunity from liability
Via
24-7 Press Release
Gilead Provides Update on Phase 3 EVOKE-01 Study
January 22, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
3 health care stocks off to strong starts in 2024
January 10, 2024
With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Will the Biotech sector sustain its momentum in 2024?
January 04, 2024
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.
Via
MarketBeat
Topics
ETFs
Gilead Sciences to Present at Upcoming Investor Conference
December 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
December 21, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
December 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
December 11, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
3 biotech powerhouses poised to thrive amid sector rebound
December 08, 2023
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.
Via
MarketBeat
Topics
ETFs
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
December 07, 2023
Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.
Via
SBWire
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
November 30, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
J&J, Gilead, BMS: A look at undervalued dividend payers
November 29, 2023
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown
Via
MarketBeat
Kite and Arcellx Announce Expansion in Strategic Partnership
November 15, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Buying the dip in high-yield Gilead Sciences
November 09, 2023
Pharma stock Gilead Sciences is well-positioned for the next few years with a growing core business, a healthy pipeline, and cash flow to sustain capital return
Via
MarketBeat
Exposures
COVID-19
Gilead Sciences to Present at Upcoming Investor Conferences
November 08, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
November 09, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
Gilead Sciences Announces Third Quarter 2023 Financial Results
November 07, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
November 06, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
November 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
November 02, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
October 31, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
October 24, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
October 20, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
October 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
October 18, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
October 17, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023
October 16, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.